Skip to main content

Table 1 Baseline and clinical characteristics

From: Cumulative lactate and hospital mortality in ICU patients

Characteristic All Survivors Nonsurvivors p valuea
  n = 2,251 n = 1846 n = 405  
Age (yr) 66 (12–98) 69 (57–76) 75 (67–81)  
Sex M : F (%) 61 : 39 61 : 39 60 : 40  
SAPS-II 38 (20–113) 33 (24–43) 51 (41–65) <0.001*
SOFA     
APACHE II 17 (10–54) 15 (11–19) 23 (17–28) <0.001*
Admission source (%)     <0.01#*
 Emergency 20.2 20.4 19.3  
 Surgical / OR 43.7 47.3 27.0  
 Medical 27.2 23.7 43.1  
 CCU 8.0 7.5 10.1  
 Other 0.9 1.1 0.5  
Diagnosis (%)     <0.01#*
 Vascular surgery 16.0 17.2 10.4  
 Abdominal surgery 22.4 23.5 17.2  
 Other surgery 9.8 10.9 4.9  
 Heart failure 14.8 12.3 26.4  
 Respiratory failure 11.8 11.5 13.4  
 GI bleeding 3.8 4.3 1.5  
 Neurological 4.5 4.6 2.7  
 Other 3.7 3.9 4.2  
 Sepsis 13.1 11.8 19.2  
Vasoactive agent (%) 33 28 57 <0.001*
LOS ICU (days) 2 (1–5) 2 (1–5) 3 (1–8) <0.001*
LOS HOSP (days) 14 (7–27) 15 (9–28) 6 (2–16) <0.001*
In-hospital mortality (%) 18    
  1. Data are presented as numbers and median (interquartile range). AUC, area under the curve; SAPS-II, simplified acute physiology score; APACHE II, acute physiology, age and chronic health evaluation; OR, operating room; CCU, cardiac care unit; GI, gastrointestinal; vasoactive agent: noradrenaline, dopamine, dobutamine, phosphodiesterase inhibitor; LOS ICU, length of stay at intensive care; LOS HOSP, length of stay at hospital; aSurvivors vs. nonsurvivors; bAll normal lactate (AUC = 0) vs. all elevated lactate (AUC > 0); *Statistically significant difference. Statistics by Chi-square tests# and Wilcoxon rank-sum tests.
\